WO2005085472A3 - Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases - Google Patents

Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases Download PDF

Info

Publication number
WO2005085472A3
WO2005085472A3 PCT/EP2005/050850 EP2005050850W WO2005085472A3 WO 2005085472 A3 WO2005085472 A3 WO 2005085472A3 EP 2005050850 W EP2005050850 W EP 2005050850W WO 2005085472 A3 WO2005085472 A3 WO 2005085472A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
protein
mal2
neurodegenerative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/050850
Other languages
French (fr)
Other versions
WO2005085472A2 (en
Inventor
Der Kammer Heinz Von
Johannes Pohlner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Priority to EP05716834A priority Critical patent/EP1721008B1/en
Priority to US10/591,678 priority patent/US20070166718A1/en
Priority to AT05716834T priority patent/ATE458834T1/en
Priority to DE602005019540T priority patent/DE602005019540D1/en
Publication of WO2005085472A2 publication Critical patent/WO2005085472A2/en
Publication of WO2005085472A3 publication Critical patent/WO2005085472A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention discloses the differential expression of the gene coding for MAL2 protein in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the MAL2 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.
PCT/EP2005/050850 2004-03-03 2005-02-28 Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases Ceased WO2005085472A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05716834A EP1721008B1 (en) 2004-03-03 2005-02-28 Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
US10/591,678 US20070166718A1 (en) 2004-03-03 2005-02-28 Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
AT05716834T ATE458834T1 (en) 2004-03-03 2005-02-28 DIAGNOSTIC AND THERAPEUTIC USE OF THE MAL2 GENE AND PROTEIN IN NEURODEGENERATIVE DISEASES
DE602005019540T DE602005019540D1 (en) 2004-03-03 2005-02-28 DIAGNOSTIC AND THERAPEUTIC USE OF THE MAL2 GENE AND PROTEIN IN NEURODEEGENERATIVE DISEASES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54914704P 2004-03-03 2004-03-03
US60/549,147 2004-03-03

Publications (2)

Publication Number Publication Date
WO2005085472A2 WO2005085472A2 (en) 2005-09-15
WO2005085472A3 true WO2005085472A3 (en) 2005-11-03

Family

ID=34919441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/050850 Ceased WO2005085472A2 (en) 2004-03-03 2005-02-28 Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases

Country Status (5)

Country Link
US (1) US20070166718A1 (en)
EP (1) EP1721008B1 (en)
AT (1) ATE458834T1 (en)
DE (1) DE602005019540D1 (en)
WO (1) WO2005085472A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045324A1 (en) * 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. CANCER TREATMENT BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CN113711036B (en) 2019-01-30 2025-03-18 真和制药有限公司 Anti-GAL3 antibodies and uses thereof
CN116157151A (en) 2020-05-26 2023-05-23 真和制药有限公司 Methods of treating inflammatory diseases by blocking galectin-3

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036440A1 (en) * 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 23 human secreted proteins
WO2001053343A1 (en) * 2000-01-18 2001-07-26 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036440A1 (en) * 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 23 human secreted proteins
WO2001053343A1 (en) * 2000-01-18 2001-07-26 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies
WO2001077137A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 11 December 2002 (2002-12-11), "Human ovarian cancer marker M472.", XP002341370, retrieved from EBI accession no. GSP:ABG96412 Database accession no. ABG96412 *
DATABASE Geneseq [online] 2 October 2001 (2001-10-02), "Human transmembrane protein cDNA clone HNALE36.", XP002341368, retrieved from EBI accession no. GSN:AAH26249 Database accession no. AAH26249 *
DATABASE Geneseq [online] 20 January 2003 (2003-01-20), "Human polypeptide SEQ ID NO 1722.", XP002341372, retrieved from EBI accession no. GSP:ABP69675 Database accession no. ABP69675 *
DATABASE Geneseq [online] 27 August 2002 (2002-08-27), "Human albumin fusion protein #1240.", XP002341371, retrieved from EBI accession no. GSP:ABG64565 Database accession no. ABG64565 *
DATABASE Geneseq [online] 8 August 2001 (2001-08-08), "Human gene 5 encoded secreted protein HETKL27, SEQ ID NO: 68.", XP002341369, retrieved from EBI accession no. GSP:AAE03822 Database accession no. AAE03822 *
ECKELMAN WILLIAM C: "The use of PET and knockout mice in the drug discovery process.", DRUG DISCOVERY TODAY. 1 MAY 2003, vol. 8, no. 9, 1 May 2003 (2003-05-01), pages 404 - 410, XP002340880, ISSN: 1359-6446 *
HUSE J T ET AL: "Neurotoxic traffic: uncovering the mechanics of amyloid production in Alzheimer's disease.", TRAFFIC (COPENHAGEN, DENMARK) FEB 2001, vol. 2, no. 2, February 2001 (2001-02-01), pages 75 - 81, XP002340881, ISSN: 1398-9219 *
MARAZUELA MONICA ET AL: "Expression and distribution of MAL2, an essential element of the machinery for basolateral-to-apical transcytosis, in human thyroid epithelial cells.", ENDOCRINOLOGY, vol. 145, no. 2, February 2004 (2004-02-01), pages 1011 - 1016, XP002340879, ISSN: 0013-7227 *
WILSON S H D ET AL: "Identification of MAL2, a Novel Member of the MAL Proteolipid Family, Though Interactions with TPD52-like Proteins in the Yeast Two-Hybrid System", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 76, no. 1-3, August 2001 (2001-08-01), pages 81 - 88, XP004459581, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
US20070166718A1 (en) 2007-07-19
WO2005085472A2 (en) 2005-09-15
EP1721008A2 (en) 2006-11-15
DE602005019540D1 (en) 2010-04-08
EP1721008B1 (en) 2010-02-24
ATE458834T1 (en) 2010-03-15

Similar Documents

Publication Publication Date Title
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2006125830A3 (en) Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
WO2005030947A3 (en) Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
WO2006134128A3 (en) Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
ATE464567T1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF F-BOX PROTEINS IN ALZHEIMER'S DISEASE AND RELATED NEURODEGENERATIVE DISEASES
ATE458834T1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF THE MAL2 GENE AND PROTEIN IN NEURODEGENERATIVE DISEASES
WO2003087403A3 (en) Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
WO2005071418A3 (en) Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases
WO2003100092A3 (en) Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
WO2003069347A3 (en) Diagnostic and therapeutic use of caps
ATE401576T1 (en) USE OF A NUCLEAR-RESTRICTED PROTEIN FOR THE DIAGNOSIS AND THERAPY OF ALZHEIMER'S DISEASE AND RELATED DEEP NEURODEGENERATION DISORDERS
ATE534751T1 (en) USE OF PRKX FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE
WO2005101014A3 (en) Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
AU2003215667A1 (en) Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases
WO2004020665A3 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
WO2004035823A3 (en) Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005716834

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007166718

Country of ref document: US

Ref document number: 10591678

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005716834

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10591678

Country of ref document: US